



Pfizer Australia Pty Ltd
Level 17, 151 Clarence Street
Sydney, NSW 2000

10 January 2025

Dear Healthcare Professional,

Shelf-life extension - ABRYSVO® recombinant respiratory syncytial virus pre-fusion F protein 120 µg/0.5 mL bivalent vaccine powder for injection vial + diluent syringe, AUST R 406624

Pfizer advises that, following the Therapeutic Goods Administration (TGA) approval, the shelf life of the below listed batches of **ABRYSVO** is extended from 24 to 36 months. The storage conditions remain unchanged and include the requirement to store ABRYSVO in a refrigerator (2°C - 8°C) prior to reconstitution. For full storage requirements before and after reconstitution, please refer to the ABRYSVO Product Information. Please refer to the table below for the updated expiry dates.

Batch number	Expiry date on package	Updated expiry date
LL2636	31.07.2025	31.07.2026
LR6779	30.06.2025	30.06.2026
LR6778	31.05.2026	31.05.2027

If you are currently in possession of ABRYSVO® stock with batch numbers different to those listed above, the expiry date remains unchanged. Please continue to use the printed expiry date on the packaging.

PLEASE REVIEW THE AUSTRALIAN PRODUCT INFORMATION BEFORE PRESCRIBING OR DISPENSING.

The ABRYSVO Product Information and Consumer Medicine Information can be found at <https://www.ebs.tga.gov.au/>.

The ABRYSVO Product Information for Healthcare Professionals is also available by scanning the QR Code below.



Adverse Event Reporting

▼ ABRYSSVO is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems. Alternatively, any adverse events which are experienced with ABRYSSVO can be reported to Pfizer on 1800 675 229 or by email to AUS.AEReporting@pfizer.com

Medical Enquiries

Should you have any questions regarding this matter, please call Pfizer Medical Information on 1800 675 229 or via www.pfizermedicalinformation.com.au

Yours sincerely,



Zirke Wiid

Senior Medical Manager
Primary Care & Vaccines
Pfizer Australia

PP-A1G-AUS-0234. 01/25.